Implementing Best Practices for Controlling Polymorphism of Chiral Drugs

摘要

Chiral drugs, which contain one or more chiral centers, comprise anrnimportant subgroup of pharmaceuticals. On account of their chirality, specialrnattention should be paid to the polymorphism and pseudopolymorphism ofrnchiral drugs. Although an enantiomer may be treated as any achiral compoundrnin terms of polymorphic characterization, the polymorphism of a racemate mayrnbe rather complicated because the racemates with different nature, e.g.rnconglomerate and racemic compound, may also be considered to bernpolymorphs. In addition, the racemic compound and the enantiomer mayrnundergo different degrees of solvation under given conditions. In this talk,rnspecial cases of polymorphism and pseudopolymorphism of chiral drugs will bernreviewed.